{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-020747","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.388741+00:00","generated_at":"2026-05-15T00:47:23.600588+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Glucotrack converts $988k note into 1.3M shares, reduces debt","bullets":["Exchanged a $988k partitioned promissory note for 1,300,000 common shares with an existing investor.","No cash or other consideration paid by the investor; debt reduction with no immediate cash outlay.","Beneficial ownership limitation at 19.9% may cause the exchange to occur in tranches.","Shares issued under Section 3(a)(9) exemption as exchange for outstanding securities.","Company also released an updated investor presentation furnished as Exhibit 99.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-020747","json":"https://secwatch.observer/filing/0001493152-26-020747.json","markdown":"https://secwatch.observer/filing/0001493152-26-020747.md","text":"https://secwatch.observer/filing/0001493152-26-020747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226020747/0001493152-26-020747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226020747/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:47:23.600588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8de36fc9183c2c599538a7187d2994dc4c72f0da","claim":"Glucotrack, Inc. entered into Exchange Agreement with an investor (effective 2026-04-29).","evidence_excerpt":"On April 29, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor in the principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (as modified, the “Original Note”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226020747/0001493152-26-020747-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001342916-26-000028","ticker":"HNOI","company_name":"HNO International, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"HNO International issues $67,500 convertible note and warrant to Monroe Street Capital","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001342916-26-000028","json":"https://secwatch.observer/filing/0001342916-26-000028.json","markdown":"https://secwatch.observer/filing/0001342916-26-000028.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1342916/000134291626000028/0001342916-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1342916/000134291626000028/hnoi8k5526.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor in the principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (as modified, the “Original Note”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226020747/0001493152-26-020747-index.htm","comparable_excerpt":"On May 5, 2026, HNO International, Inc. (the \"Company\") entered into a Securities Purchase Agreement (the \"MSC Purchase Agreement\") with Monroe Street Capital Partners, LP, a Delaware limited partnership (the \"MSC Buyer\"), pursuant to which the Company issued to the MSC Buyer a Convertible Promissory Note in the principal amount of $67,500","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1342916/000134291626000028/0001342916-26-000028-index.htm"}},{"accession":"0000785161-26-000161","ticker":"EHC","company_name":"Encompass Health Corp","filed_at":"2026-06-01T20:26:16+00:00","headline":"Encompass Health issues $500M 5.875% notes due 2034; to redeem $400M of 4.500% notes due 2028","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000785161-26-000161","json":"https://secwatch.observer/filing/0000785161-26-000161.json","markdown":"https://secwatch.observer/filing/0000785161-26-000161.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/785161/000078516126000161/0000785161-26-000161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/785161/000078516126000161/ehc-20260529.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor in the principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (as modified, the “Original Note”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226020747/0001493152-26-020747-index.htm","comparable_excerpt":"On May 29, 2026, Encompass Health Corporation (the \"Company\") completed the issuance and sale of $500 million in aggregate principal amount of its 5.875% Senior Notes due 2034 (the \"Notes\"), along with the related guarantees of the Notes by certain of the Company's subsidiaries (the \"Guarantees\"), in a private offering.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/785161/000078516126000161/0000785161-26-000161-index.htm"}},{"accession":"0001654954-26-004632","ticker":"PED","company_name":"PEDEVCO CORP","filed_at":"2026-05-08T23:59:59+00:00","headline":"PEDEVCO amends credit facility: EBITDAX definition, redetermination schedule, and reserve report timeline updated","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-26-004632","json":"https://secwatch.observer/filing/0001654954-26-004632.json","markdown":"https://secwatch.observer/filing/0001654954-26-004632.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1141197/000165495426004632/0001654954-26-004632-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1141197/000165495426004632/ped_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor in the principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (as modified, the “Original Note”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226020747/0001493152-26-020747-index.htm","comparable_excerpt":"On May 5, 2026 (the “Second Amendment Effective Date”), PEDEVCO Corp., a Texas corporation (the “Company”), entered into a Second Amendment to Credit Agreement (the “Second Amendment”) with Citibank, N.A., as administrative agent (the “Administrative Agent”), each of the guarantors party thereto, and each of the lenders party thereto.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1141197/000165495426004632/0001654954-26-004632-index.htm"}},{"accession":"0001193125-26-212154","ticker":null,"company_name":"Apollo Debt Solutions BDC","filed_at":"2026-05-07T23:59:59+00:00","headline":"Apollo Debt Solutions BDC issues $300M 6.550% notes due 2032 at 100.604% of face value","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-212154","json":"https://secwatch.observer/filing/0001193125-26-212154.json","markdown":"https://secwatch.observer/filing/0001193125-26-212154.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837532/000119312526212154/0001193125-26-212154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837532/000119312526212154/d127793d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor in the principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (as modified, the “Original Note”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226020747/0001493152-26-020747-index.htm","comparable_excerpt":"the Fund entered into a Registration Rights Agreement, dated as of May 7, 2026 (the “ Registration Rights Agreement ”), with Goldman Sachs & Co. LLC, ING Financial Markets LLC, Truist Securities, Inc. and Wells Fargo Securities, LLC as the representatives of the Initial Purchasers of the Notes.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1837532/000119312526212154/0001193125-26-212154-index.htm"}},{"accession":"0001193125-26-251718","ticker":"PFLT","company_name":"PennantPark Floating Rate Capital Ltd.","filed_at":"2026-06-01T21:09:48+00:00","headline":"PennantPark Floating Rate Capital issues $105M 7.375% Notes due 2031","event_type":"debt","sec_items":["1.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251718","json":"https://secwatch.observer/filing/0001193125-26-251718.json","markdown":"https://secwatch.observer/filing/0001193125-26-251718.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1504619/000119312526251718/0001193125-26-251718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1504619/000119312526251718/d37162d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor in the principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (as modified, the “Original Note”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226020747/0001493152-26-020747-index.htm","comparable_excerpt":"On June 1, 2026, PennantPark Floating Rate Capital Ltd. (the “Company”) and Equiniti Trust Company, LLC (the “Trustee”) entered into a Third Supplemental Indenture (the “Third Supplemental Indenture”) to the Indenture between the Company and the Trustee, dated March 23, 2021 (the “Base Indenture,” and together with the Third Supplemental Indenture, the “Indenture”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1504619/000119312526251718/0001193125-26-251718-index.htm"}},{"accession":"0000932696-26-000063","ticker":"NSIT","company_name":"INSIGHT ENTERPRISES INC","filed_at":"2026-06-01T17:36:39+00:00","headline":"Insight Enterprises adds $100M swingline sub-facility via seventh amendment to ABL credit agreement","event_type":"debt","sec_items":["1.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000932696-26-000063","json":"https://secwatch.observer/filing/0000932696-26-000063.json","markdown":"https://secwatch.observer/filing/0000932696-26-000063.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/932696/000093269626000063/0000932696-26-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/932696/000093269626000063/nsit-20260528.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor in the principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (as modified, the “Original Note”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226020747/0001493152-26-020747-index.htm","comparable_excerpt":"On May 28, 2026, Insight Enterprises, Inc. (“Insight”) entered into a seventh amendment to credit agreement (the “Seventh Amendment”) with JPMorgan Chase Bank, N.A., as Administrative Agent (the “Agent”), the lenders party thereto, certain of Insight’s subsidiaries organized in the United States, the United Kingdom, the Netherlands and Australia, as additional borrowers (collectively with Insight, the “Borrowers”), and certain of Insight’s subsidiaries organized in the United States, the United Kingdom, the Netherlands, Australia and Canada, as guarantors (collectively, the “Guarantors”), which amends the credit agreement, dated as of August 30, 2019 (as amended the “ABL Credit Agreement”)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/932696/000093269626000063/0000932696-26-000063-index.htm"}},{"accession":"0001104659-26-057938","ticker":"DGX","company_name":"QUEST DIAGNOSTICS INC","filed_at":"2026-05-08T23:59:59+00:00","headline":"Quest Diagnostics issues $500M of 5.000% senior notes due 2036","event_type":"debt","sec_items":["1.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057938","json":"https://secwatch.observer/filing/0001104659-26-057938.json","markdown":"https://secwatch.observer/filing/0001104659-26-057938.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022079/000110465926057938/0001104659-26-057938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022079/000110465926057938/tm2613096d2_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor in the principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (as modified, the “Original Note”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226020747/0001493152-26-020747-index.htm","comparable_excerpt":"On May 6, 2026, Quest Diagnostics Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1022079/000110465926057938/0001104659-26-057938-index.htm"}},{"accession":"0001213900-26-053916","ticker":"CTXR","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Citius Pharma subsidiary amends $3.8M note, adds conversion at $0.90, subordinates to senior debt","event_type":"debt","sec_items":["1.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053916","json":"https://secwatch.observer/filing/0001213900-26-053916.json","markdown":"https://secwatch.observer/filing/0001213900-26-053916.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026053916/0001213900-26-053916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026053916/ea0289731-8k_citius.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 29, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor in the principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (as modified, the “Original Note”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226020747/0001493152-26-020747-index.htm","comparable_excerpt":"the Company and Citius Oncology entered into a Third Amendment to Promissory Note (the “Third Amendment”), which amends the promissory note, dated August 16, 2024, as previously amended on September 10, 2025 and December 10, 2025, issued by the Citius Oncology to the Company in the original principal amount of $3,800,111 (the “Promissory Note”)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026053916/0001213900-26-053916-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}